Previous 10 | Next 10 |
2023-04-18 08:31:08 ET The U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to Madrigal Pharmaceuticals' ( NASDAQ: MDGL ) resmetirom to treat patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis. The company also said ...
CONSHOHOCKEN, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that resmetirom has received Breakthrough Therapy designation from th...
2023-04-04 22:01:45 ET Summary Baker Brothers’ 13F portfolio value increased from $15.27B to $16.65B this quarter. Replimune Group stake was substantially increased this quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to alm...
2023-04-04 07:56:37 ET Summary Following positive data for its obesity drug (VK2735), Viking Therapeutics shares rallied aggressively. In Q2, Viking is poised to release its Phase 2b (VOYAGE) trial data of VK2809 for non-alcoholic steatohepatitis. Operating at an inflection po...
2023-03-30 11:16:20 ET Summary Madrigal's share price rocketed >350% in December last year after positive data from a Phase 3 study of lead drug Resmetirom in NASH. NASH is a massive market opportunity - close to 50m people in the US and Europe are estimated to have the disease...
2023-03-29 23:40:24 ET Summary NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million i...
2023-03-29 07:45:00 ET Viking Therapeutics (NASDAQ: VKTX) , a small-cap biotech, has been on quite the ride over the past few months. Thanks to a positive late-stage trial in nonalcoholic steatohepatitis (NASH) from rival Madrigal Pharmaceuticals (NASDAQ: MDGL) last Dece...
2023-03-27 17:05:01 ET Gainers: Near Intelligence ( NIR ) +12% . Lyft ( LYFT ) +5% . Madrigal Pharmaceuticals ( MDGL ) +4% . Purple Innovation ( PRPL ) +4% . Pyxis Oncology ( PYXS ) +3% . Losers: Freightcar America ( RA...
2023-03-22 07:44:35 ET Liver disease drug developer 89bio ( NASDAQ: ETNB ) added ~47% on Wednesday after announcing topline data from its Phase 2b ENLIVEN trial for pegozafermin in patients with nonalcoholic steatohepatitis (NASH). The trial involved 219 patients who wer...
2023-03-21 08:13:14 ET Summary TERN has a growing pipeline of early-stage assets against validated targets. TERN's internal discovery team has been productive at developing small molecules against key targets in big markets. TERN has an important NASH readout coming in Q3 23. ...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement...
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...